bioAffinity Technologies, Inc. Increase (Decrease) in Accounts and Other Receivables
bioAffinity Technologies, Inc. (BIAF) reported Increase (Decrease) in Accounts and Other Receivables of $352.86 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables · last filed 2026-08-07
- bioAffinity Technologies, Inc. increase (decrease) in accounts and other receivables for the quarter ending 2026-06-30 was $209.59K.
- bioAffinity Technologies, Inc. increase (decrease) in accounts and other receivables for the quarter ending 2026-03-31 was $143.27K.
- bioAffinity Technologies, Inc. increase (decrease) in accounts and other receivables for the quarter ending 2025-12-31 was $92.97K.
- bioAffinity Technologies, Inc. increase (decrease) in accounts and other receivables for the quarter ending 2025-09-30 was $27.12K.
- bioAffinity Technologies, Inc. increase (decrease) in accounts and other receivables for fiscal 2025 was -$597.24K, a 282.35% decline from fiscal 2024.
- bioAffinity Technologies, Inc. increase (decrease) in accounts and other receivables for fiscal 2024 was $327.53K.
- bioAffinity Technologies, Inc. increase (decrease) in accounts and other receivables for fiscal 2023 was -$311.37K, a 3575.45% decline from fiscal 2022.
- bioAffinity Technologies, Inc. increase (decrease) in accounts and other receivables for fiscal 2022 was $8.96K.
| Period end | Increase (Decrease) in Accounts and Other Receivables 3 month | Increase (Decrease) in Accounts and Other Receivables 6 month | Increase (Decrease) in Accounts and Other Receivables 9 month | Increase (Decrease) in Accounts and Other Receivables 12 month |
|---|---|---|---|---|
| 2026-06-30 | $209.59K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $352.86K 10-Q · filed 2026-08-07 | $445.83K derived: sum of 3 quarters · filed 2026-08-07 | $472.95K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $143.27K 10-Q · filed 2026-05-11 | $236.25K derived: sum of 2 quarters · filed 2026-05-11 | $263.37K derived: sum of 3 quarters · filed 2026-05-11 | -$278.51K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $92.97K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $120.09K derived: sum of 2 quarters · filed 2026-03-16 | -$421.78K derived: sum of 3 quarters · filed 2026-08-07 | -$597.24K 10-K · filed 2026-03-16 |
| 2025-09-30 | $27.12K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$514.75K derived: sum of 2 quarters · filed 2026-08-07 | -$690.21K 10-Q · filed 2025-11-14 | -$878.18K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | -$541.88K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$717.34K 10-Q · filed 2026-08-07 | -$905.30K derived: sum of 3 quarters · filed 2026-08-07 | -$1.17M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$175.46K 10-Q · filed 2026-05-11 | -$363.42K derived: sum of 2 quarters · filed 2026-05-11 | -$631.88K derived: sum of 3 quarters · filed 2026-05-11 | -$159.87K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$187.96K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$456.42K derived: sum of 2 quarters · filed 2026-03-16 | $15.60K derived: sum of 3 quarters · filed 2026-03-16 | $327.53K 10-K · filed 2026-03-16 |
| 2024-09-30 | -$268.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $203.56K derived: sum of 2 quarters · filed 2025-11-14 | $515.49K 10-Q · filed 2025-11-14 | $275.97K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $472.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $783.95K 10-Q · filed 2025-08-14 | $544.43K derived: sum of 3 quarters · filed 2025-08-14 | $392.84K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $311.94K 10-Q · filed 2025-05-15 | $72.41K derived: sum of 2 quarters · filed 2025-05-15 | -$79.17K derived: sum of 3 quarters · filed 2025-05-15 | $31.00 derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$239.53K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$391.11K derived: sum of 2 quarters · filed 2025-03-31 | -$311.90K derived: sum of 3 quarters · filed 2025-03-31 | -$311.37K 10-K · filed 2025-03-31 |
| 2023-09-30 | -$151.58K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$72.38K derived: sum of 2 quarters · filed 2024-11-14 | -$71.84K 10-Q · filed 2024-11-14 | -$71.28K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $79.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $79.74K 10-Q · filed 2024-08-14 | $80.30K derived: sum of 3 quarters · filed 2024-08-14 | $82.42K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $538.00 10-Q · filed 2024-05-15 | $1.10K derived: sum of 2 quarters · filed 2024-05-15 | $3.21K derived: sum of 3 quarters · filed 2024-05-15 | $4.17K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $559.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $2.67K derived: sum of 2 quarters · filed 2024-04-01 | $3.63K derived: sum of 3 quarters · filed 2024-04-01 | $8.96K 10-K · filed 2024-04-01 |
| 2022-09-30 | $2.11K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $3.07K derived: sum of 2 quarters · filed 2023-11-14 | $8.40K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $956.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $6.29K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $5.33K 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |